OSCA - Olaparib Standard of CAre Study

AstraZeneca

Status: Completed

Conditions: Platinum-sensitive Recurrent Serous Ovarian Cancer

Treatments: Other: Data Collection

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02262273

D0816R00004

Details and patient eligibility

About

This study will be carried out as a retrospective, non-interventional observational review of medical records for patients in multiple countries with platinum-sensitive recurrent serous ovarian cancer. The objectives are to describe in a real-world population, treatment patterns, BRCA mutation testing and results, overall survival, health care utilization and also to estimate rates of selected treatment- and/or disease-related side effects

Enrollment: 2,123 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. First determined to have platinum-sensitive recurrent serous ovarian cancer between January 1, 2009, and December 31, 2013 (study entry period), as defined by no evidence of disease progression for at least 6 months after completion of a first-line platinum-based chemotherapy regimen; the first date of platinum-sensitive recurrence between January 1, 2009 and December 31, 2013 will define the study index date.
2. At least 18 years of age on the index date.
3. Fully documented medical history related to the patient's ovarian cancer treatment beginning with initial diagnosis of serous ovarian cancer.
4. Patients can be either alive or deceased at the time of medical record abstraction.

Exclusion criteria

1. Ever taken an investigational product as part of an interventional clinical trial for ovarian cancer.

Trial design

2,123 participants in 1 patient group

Serous ovarian cancer:

Description:

Women with platinum-sensitive recurrent serous ovarian cancer

Treatment:

Other: Data Collection